JACQUELINE TEBEEST: Open Payments
NPI 1831591684 · BLUE SPRINGS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$663 in 37 payments from 17 companies in 2025. Trend: 2023 $100 · 2024 $553 · 2025 $663
Food & beverage: $663
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $181 |
| PFIZER INC. | 5 | $80 |
| Abbott Laboratories | 3 | $62 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Lilly USA, LLC | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Novartis Pharmaceuticals Corporation | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
Products named: UBRELVY, QULIPTA, FREESTYLE LIBRE 3, NURTEC ODT, NEXLETOL, AUSTEDO XR, CAPLYTA, MOUNJARO.
Industry payments across MO — which companies pay providers there.
